RxDoctor Payments Data

Richard Kiel, MD

Advanced Heart Failure and Transplant Cardiology · Fresno, CANPI 1073846747

Payments from drug & device makers

$28,861in general payments, 2019–2025

Across 169 payments — averaging $170.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$13K
  • Abbott$8K
  • Amgen$3K
  • Abiomed$2K
  • Actelion Pharmaceuticals US, Inc.$337
  • United Therapeutics Corporation$292
  • plus $2K from 17 others

What the payments were for

  • Travel & lodging$98318%
  • Food & beverage$4,35980%
  • Education$1022%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,861 in reported general payments places this provider in the 45th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California

Medicare billing

Part B allowed, 2024
$100,296
Medicare patients
577
Services billed
1,222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan22$277,436
Orenitram ErTreprostinil Diolamine21$274,719
EntrestoSacubitril/Valsartan161$215,327
JardianceEmpagliflozin140$161,563
EliquisApixaban63$76,363
ZerbaxaCeftolozane/Tazobactam11$50,711
FarxigaDapagliflozin Propanediol45$39,465
WegovySemaglutide18$24,943
Repatha SureclickEvolocumab39$22,084
OzempicSemaglutide22$20,057
XareltoRivaroxaban11$11,611
Bumetanide123$6,384
Metoprolol Succinate190$3,280
Potassium Chloride111$2,960
Eplerenone42$2,666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$337$277,43622 claims
NovartisEntresto$259$215,327161 claims
Boehringer IngelheimJardiance$290$161,563140 claims
PfizerEliquis$53$76,36363 claims
MerckZerbaxa$51$50,71111 claims
Novo NordiskWegovy, Ozempic$111$45,00040 claims
AstraZenecaFarxiga$15$39,46545 claims
Johnson & JohnsonXarelto$185$11,61111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 111 advanced heart failure and transplant cardiology providers in California.

Other advanced heart failure and transplant cardiology in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →